Athira Pharma, Inc.

Contributing Author

Recent Articles by Athira Pharma, Inc.

Dec-18	Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million ATHA GlobeNewswire
Nov-06	Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update ATHA GlobeNewswire
Sep-11	Athira Pharma Announces Reverse Stock Split ATHA GlobeNewswire
Aug-14	Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025 ATHA GlobeNewswire
Aug-07	Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update ATHA GlobeNewswire
May-13	Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit ATHA GlobeNewswire
May-09	Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates ATHA GlobeNewswire